Nurix Therapeutics (NASDAQ:NRIX) Upgraded to “Hold” at Leerink Partnrs

Nurix Therapeutics (NASDAQ:NRIX) was upgraded by equities researchers at Leerink Partnrs to a “hold” rating in a research note issued to investors on Monday,Zacks.com reports. Leerink Partnrs also issued estimates for Nurix Therapeutics’ Q1 2025 earnings at ($0.89) EPS and Q2 2025 earnings at ($0.93) EPS.

A number of other equities research analysts also recently weighed in on NRIX. Royal Bank of Canada raised their target price on Nurix Therapeutics from $26.00 to $27.00 and gave the company an “outperform” rating in a report on Wednesday, January 29th. HC Wainwright raised their target price on Nurix Therapeutics from $35.00 to $36.00 and gave the company a “buy” rating in a report on Wednesday, January 29th. Stephens reaffirmed an “overweight” rating and issued a $31.00 target price on shares of Nurix Therapeutics in a report on Tuesday, January 21st. BTIG Research assumed coverage on Nurix Therapeutics in a report on Tuesday, December 10th. They issued a “buy” rating and a $35.00 target price on the stock. Finally, Morgan Stanley raised their price objective on Nurix Therapeutics from $16.00 to $17.00 and gave the company an “equal weight” rating in a report on Monday, February 3rd. Three analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to MarketBeat, Nurix Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $30.88.

Nurix Therapeutics Price Performance

Nurix Therapeutics stock opened at $13.66 on Monday. The stock’s fifty day moving average price is $17.33 and its two-hundred day moving average price is $20.98. Nurix Therapeutics has a one year low of $11.90 and a one year high of $29.56. The firm has a market cap of $1.04 billion, a PE ratio of -4.73 and a beta of 2.18.

Nurix Therapeutics (NASDAQ:NRIX) last posted its quarterly earnings data on Tuesday, January 28th. The company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.08). Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. Sell-side analysts expect that Nurix Therapeutics will post -2.99 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Nurix Therapeutics news, CFO Houte Hans Van sold 5,825 shares of Nurix Therapeutics stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $14.49, for a total transaction of $84,404.25. Following the transaction, the chief financial officer now directly owns 33,724 shares of the company’s stock, valued at approximately $488,660.76. The trade was a 14.73 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Gwenn Hansen sold 3,690 shares of Nurix Therapeutics stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $19.85, for a total value of $73,246.50. Following the transaction, the insider now directly owns 55,937 shares in the company, valued at $1,110,349.45. The trade was a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 12,326 shares of company stock valued at $213,449. 7.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. US Bancorp DE raised its position in shares of Nurix Therapeutics by 144.7% in the 4th quarter. US Bancorp DE now owns 1,424 shares of the company’s stock worth $27,000 after acquiring an additional 842 shares in the last quarter. GF Fund Management CO. LTD. bought a new position in shares of Nurix Therapeutics in the 4th quarter worth about $28,000. Quarry LP raised its position in shares of Nurix Therapeutics by 3,746.2% in the 3rd quarter. Quarry LP now owns 2,500 shares of the company’s stock worth $56,000 after acquiring an additional 2,435 shares in the last quarter. Aquatic Capital Management LLC bought a new position in shares of Nurix Therapeutics in the 4th quarter worth about $87,000. Finally, Summit Investment Advisors Inc. raised its position in shares of Nurix Therapeutics by 13.6% in the 4th quarter. Summit Investment Advisors Inc. now owns 7,345 shares of the company’s stock worth $138,000 after acquiring an additional 877 shares in the last quarter.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.